Sinopharm Group Co. Ltd.

Symbol: SHTDY

PNK

13.295

USD

Market price today

  • 33.7198

    P/E Ratio

  • 1.0210

    PEG Ratio

  • 8.20B

    MRK Cap

  • 0.01%

    DIV Yield

Sinopharm Group Co. Ltd. (SHTDY) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.08%

Operating Profit Margin

0.03%

Net Profit Margin

0.01%

Return on Assets

0.02%

Return on Equity

0.12%

Return on Capital Employed

0.14%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Distribution
CEO:Mr. Qingming Yu
Full-time employees:115959
City:Shanghai
Address:Sinopharm Group Building
IPO:2016-08-25
CIK:

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

General Outlook

When we look at how much money they make before expenses, they keep 0.080% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.034%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.015%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.022% return, is a testament to Sinopharm Group Co. Ltd.'s adeptness in optimizing resource deployment. Sinopharm Group Co. Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.122%. Furthermore, the proficiency of Sinopharm Group Co. Ltd. in capital utilization is underscored by a remarkable 0.141% return on capital employed.

Liquidity Ratios

Analyzing SHTDY liquidity ratios reveals its financial health of the firm. The current ratio of 136.04% gauges short-term asset coverage for liabilities. The quick ratio (105.05%) assesses immediate liquidity, while the cash ratio (18.25%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio136.04%
Quick Ratio105.05%
Cash Ratio18.25%

Profitability Ratios

SHTDY profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 3.18% underscores its earnings before tax deductions. The effective tax rate stands at 23.16%, revealing its tax efficiency. The net income per EBT, 46.76%, and the EBT per EBIT, 92.97%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 3.42%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin3.18%
Effective Tax Rate23.16%
Net Income per EBT46.76%
EBT per EBIT92.97%
EBIT per Revenue3.42%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.36, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding105
Days of Inventory Outstanding43
Operating Cycle184.74
Days of Payables Outstanding99
Cash Conversion Cycle86
Receivables Turnover2.57
Payables Turnover3.68
Inventory Turnover8.52
Fixed Asset Turnover34.81
Asset Turnover1.45

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 3.33, and free cash flow per share, 2.60, depict cash generation on a per-share basis. The cash per share value, 15.67, showcases liquidity position. A payout ratio of 0.44 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.02, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share3.33
Free Cash Flow per Share2.60
Cash per Share15.67
Payout Ratio0.44
Operating Cash Flow Sales Ratio0.02
Free Cash Flow to Operating Cash Flow Ratio0.78
Cash Flow Coverage Ratio0.13
Short Term Coverage Ratio0.16
Capital Expenditure Coverage Ratio4.58
Dividend Paid and Capex Coverage Ratio1.69
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 19.62%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 19.17%, and total debt to capitalization, 51.56%, ratios shed light on its capital structure. An interest coverage of 55.68 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio19.62%
Debt Equity Ratio1.06
Long Term Debt to Capitalization19.17%
Total Debt to Capitalization51.56%
Interest Coverage55.68
Cash Flow to Debt Ratio0.13
Company Equity Multiplier5.43

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 955.84, provides a glimpse into top-line earnings distributed across each share. Net income per share, 14.51, reflects the portion of profit attributed to each share. The book value per share, 119.50, represents the net asset value distributed per share, while the tangible book value per share, 173.48, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share955.84
Net Income Per Share14.51
Book Value Per Share119.50
Tangible Book Value Per Share173.48
Shareholders Equity Per Share119.50
Interest Debt Per Share122.95
Capex Per Share-3.74

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 8.05%, indicates top-line expansion, while the gross profit growth, 2.27%, reveals profitability trends. EBIT growth, -1.92%, and operating income growth, -1.92%, offer insights into operational profitability progression. The net income growth, 6.19%, showcases bottom-line expansion, and the EPS growth, 6.23%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth8.05%
Gross Profit Growth2.27%
EBIT Growth-1.92%
Operating Income Growth-1.92%
Net Income Growth6.19%
EPS Growth6.23%
EPS Diluted Growth6.23%
Dividends per Share Growth9.33%
Operating Cash Flow Growth-18.08%
Free Cash Flow Growth-20.00%
10-Year Revenue Growth per Share189.09%
5-Year Revenue Growth per Share64.67%
3-Year Revenue Growth per Share30.31%
10-Year Operating CF Growth per Share181.02%
5-Year Operating CF Growth per Share346.96%
3-Year Operating CF Growth per Share53.49%
10-Year Net Income Growth per Share225.37%
5-Year Net Income Growth per Share47.53%
3-Year Net Income Growth per Share25.59%
10-Year Shareholders Equity Growth per Share176.44%
5-Year Shareholders Equity Growth per Share65.63%
3-Year Shareholders Equity Growth per Share31.93%
10-Year Dividend per Share Growth per Share222.25%
5-Year Dividend per Share Growth per Share54.30%
3-Year Dividend per Share Growth per Share36.78%
Receivables Growth-7.98%
Inventory Growth-1.47%
Asset Growth5.10%
Book Value per Share Growth9.57%
Debt Growth6.02%
SGA Expenses Growth5.01%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 67,780,199,073.168, captures the company's total value, considering both debt and equity. Income quality, 0.88, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 3.14%, indicates the value of non-physical assets, and capex to operating cash flow, -13.60%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value67,780,199,073.168
Income Quality0.88
Sales General and Administrative to Revenue0.01
Intangibles to Total Assets3.14%
Capex to Operating Cash Flow-13.60%
Capex to Revenue-0.39%
Capex to Depreciation-52.73%
Graham Number197.49
Return on Tangible Assets2.44%
Graham Net Net-47.92
Working Capital95,344,463,000
Tangible Asset Value108,274,644,000
Net Current Asset Value73,759,001,000
Invested Capital1
Average Receivables193,850,120,729
Average Payables149,682,061,000
Average Inventory60,476,739,500
Days Sales Outstanding114
Days Payables Outstanding103
Days of Inventory On Hand40
ROIC10.48%
ROE0.12%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 3.93, and the price to book ratio, 3.93, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.10, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 7.29, and price to operating cash flows, 28.84, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio3.93
Price to Book Ratio3.93
Price to Sales Ratio0.10
Price Cash Flow Ratio28.84
Price Earnings to Growth Ratio1.02
Enterprise Value Multiple1.19
Price Fair Value3.93
Price to Operating Cash Flow Ratio28.84
Price to Free Cash Flows Ratio7.29
Price to Tangible Book Ratio0.78
Enterprise Value to Sales0.11
Enterprise Value Over EBITDA2.39
EV to Operating Cash Flow3.95
Earnings Yield15.66%
Free Cash Flow Yield25.67%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sinopharm Group Co. Ltd. (SHTDY) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 33.720 in 2024.

What is the ticker symbol of Sinopharm Group Co. Ltd. stock?

The ticker symbol of Sinopharm Group Co. Ltd. stock is SHTDY.

What is company IPO date?

IPO date of Sinopharm Group Co. Ltd. is 2016-08-25.

What is company current share price?

Current share price is 13.295 USD.

What is stock market cap today?

The market cap of stock today is 8202808117.000.

What is PEG ratio in 2024?

The current 1.021 is 1.021 in 2024.

What is the number of employees in 2024?

In 2024 the company has 115959.